CRVS
Corvus Pharmaceuticals, Inc.Company Information
- Company Name
- Corvus Pharmaceuticals, Inc.
- CIK
- CIK0001626971
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CRVS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CRVS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-11
- Last sale
- 2025-06-27
- Shares purchased (TTM)
- 28,632
- Shares sold (TTM)
- 2,352,664
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 66,930,632
- Shares outstanding
- 92,368,013
- Ownership
- 72.46%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 2.16%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 40 | 5 | 3 | 15 | 5 | 9 | 5 | 15 | 7 | 13 | 20 | ||||||
| Available For Sale Securities Debt Securities | - | - | - | 63 | 60 | 39 | 43 | 37 | 32 | 15 | 15 | 12 | ||||||
| Available For Sale Securities Debt Securities Current | 196 | 197 | 52 | - | - | - | 43 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 3 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 221 | 240 | 58 | 67 | 76 | 45 | 54 | 43 | 48 | 23 | 28 | 33 | ||||||
| Property Plant And Equipment Net | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | ||||||
| Equity Method Investments | 15 | 10 | 11 | 12 | 12 | 12 | 13 | 15 | 15 | 16 | 16 | 17 | ||||||
| Other Assets Noncurrent | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 239 | 253 | 71 | 80 | 89 | 59 | 69 | 59 | 65 | 40 | 46 | 52 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 2 | 2 | 3 | 1 | 3 | 2 | 1 | 2 | 2 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 9 | 7 | 6 | 6 | 5 | 4 | 4 | - | - | - | 4 | - | ||||||
| Warrants And Rights Outstanding | - | - | - | - | - | 4 | 29 | 40 | 7 | - | - | - | ||||||
| Liabilities Current | 14 | 12 | 9 | 8 | 9 | 9 | 35 | 46 | 13 | 7 | 7 | 7 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 0 | ||||||
| Liabilities | 14 | 13 | 10 | 9 | 9 | 10 | 36 | 46 | 13 | 7 | 7 | 8 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 671 | 668 | 474 | 473 | 471 | 432 | 431 | 398 | 397 | 375 | 374 | 374 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -444 | -426 | -412 | -400 | -390 | -382 | -397 | -385 | -345 | -340 | -335 | -328 | ||||||
| Stockholders Equity | 225 | 241 | 61 | 72 | 80 | 49 | 33 | 12 | 51 | 33 | 39 | 44 | ||||||
| Liabilities And Stockholders Equity | 239 | 253 | 71 | 80 | 89 | 59 | 69 | 59 | 65 | 40 | 46 | 52 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | ||||||
| Common Stock Shares Issued | 84 | 84 | 75 | 75 | 75 | 68 | 68 | 63 | 63 | 49 | 49 | 49 | ||||||
| Shares Outstanding | 84 | 84 | 75 | 75 | 75 | 68 | 68 | 63 | 63 | 49 | 49 | 49 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCorvus Pharmaceuticals, Inc. (CRVS) — SEC Financial Statements & Analysis
Corvus Pharmaceuticals, Inc. (CRVS) is a pharmaceutical preparations company, incorporated in DE. Corvus Pharmaceuticals, Inc. trades on Nasdaq as: CRVS. Corvus Pharmaceuticals, Inc. (CRVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Corvus Pharmaceuticals, Inc. carries a market cap of $1.38B, a P/E ratio of -25.49x, a P/B ratio of 6.12x, an enterprise value of $1.36B, and an EV/EBITDA multiple of -23.94x. On profitability, it posts a Return on Equity (ROE) of -35.43%, a Return on Assets (ROA) of -32.93%, and a Return on Invested Capital (ROIC) of -41.89%. Per share, it reports EPS of $-0.59, diluted EPS of $-0.59, free cash flow per share of $-0.49, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 19.93% year-over-year and EPS growth of 0.98% year-over-year. On the balance sheet, it maintains a current ratio of 16.16x, a quick ratio of 15.74x, working capital of $207.29M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, free cash flow of $-45.23M (TTM), and net debt of $-18.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.38B
- P/E TTM
- -25.49x
- EPS TTM
- $-0.59
- P/B TTM
- 6.12x
- ROE TTM
- -35.43%
- ROA TTM
- -32.93%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-45.23M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Corvus Pharmaceuticals, Inc. in?
Corvus Pharmaceuticals, Inc. (CRVS) operates in the Pharmaceutical Preparations industry.
What exchange does CRVS trade on?
Corvus Pharmaceuticals, Inc. (CRVS) trades on the Nasdaq.
Where is Corvus Pharmaceuticals, Inc. incorporated?
Corvus Pharmaceuticals, Inc. is incorporated in DE.
When was Corvus Pharmaceuticals, Inc. (CRVS)'s most recent SEC filing?
Corvus Pharmaceuticals, Inc. (CRVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CRVS's market cap?
Corvus Pharmaceuticals, Inc. (CRVS) has a market capitalization of $1.38B as of 2026-06-30.
What is CRVS's EPS (earnings per share)?
Corvus Pharmaceuticals, Inc. (CRVS)'s trailing twelve month EPS is $-0.59 as of 2026-06-30.
What is CRVS's ROE (return on equity)?
Corvus Pharmaceuticals, Inc. (CRVS)'s trailing twelve month Return on Equity (ROE) is -35.43% as of 2026-06-30.
What is CRVS's ROA (return on assets)?
Corvus Pharmaceuticals, Inc. (CRVS)'s trailing twelve month Return on Assets (ROA) is -32.93% as of 2026-06-30.
What is CRVS's ROIC (return on invested capital)?
Corvus Pharmaceuticals, Inc. (CRVS)'s trailing twelve month Return on Invested Capital (ROIC) is -41.89% as of 2026-06-30.
What is CRVS's EV/EBITDA?
Corvus Pharmaceuticals, Inc. (CRVS)'s trailing twelve month EV/EBITDA is -23.94x as of 2026-06-30.